Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Post-approval studies for Alzheimer’s drugs are mandatory clinical trials that verify whether a new treatment actually slows cognitive decline in real patients—and if it fails to deliver, the FDA can withdraw approval. These studies exist because the Accelerated Approval pathway allows drugs to reach patients faster based on promising early data, with the understanding that sponsors must prove the benefit holds up in larger, longer trials.
Leqembi (lecanemab-irmb) exemplifies this process: it entered the market under Accelerated Approval in 2023 with conditional status, then successfully completed its confirmatory trial and was converted to traditional FDA approval in 2024, confirming that the drug slowed cognitive decline by 27% over 18 months in early Alzheimer’s disease. The stakes of these studies matter because the drugs in question are not miracle cures—they are complex monoclonal antibodies that target amyloid protein buildup in the brain, and their real-world safety profile is still being defined. The FDA grants sponsors up to 9 years to complete post-approval trials, but failure carries consequences: Biogen abandoned aducanumab, an earlier anti-amyloid therapy, when the company voluntarily terminated its confirmatory trial in 2021 rather than face likely disapproval based on inconclusive data.
Table of Contents
- Why the FDA Requires Post-Market Verification of Alzheimer’s Treatments
- The Hidden Safety Monitoring Burden: ARIA and Mandatory Imaging
- What Real-World Data Tells Us That Clinical Trials May Not Reveal
- The Practical Cost and Access Implications of Post-Approval Monitoring
- The Limits of Current Trials: Prevention Remains Unproven
- What Happened to Aducanumab and Other Failed Programs
- 2026 Milestones and What the FDA Is Monitoring This Year
Why the FDA Requires Post-Market Verification of Alzheimer’s Treatments
The Accelerated Approval pathway exists to speed access to drugs treating serious conditions when early evidence is promising. For anti-amyloid monoclonal antibodies targeting Alzheimer’s disease, the FDA approved lecanemab and donanemab under this conditional track because they showed they could reduce amyloid in the brain and slow decline in early symptomatic disease. The trade-off is that the sponsor agrees to run a full confirmatory Phase 3 trial to verify clinical benefit—not just biomarker changes, but actual slowing of cognitive decline that patients and families can observe. If that trial fails to show what the earlier data suggested, the FDA has the authority to pull the drug from the market.
The regulatory timelines are substantial. Lecanemab underwent the CLARITY AD Phase 3 trial, which tracked 1,795 patients with mild cognitive impairment or mild dementia stage Alzheimer’s disease over 18 months, ultimately demonstrating a 27% slowing of cognitive decline compared to placebo. That successful confirmatory trial led to the conversion from accelerated to traditional approval, which signals to the medical community and to patients that the drug’s benefit is now firmly established in the regulatory record. Donanemab, approved more recently, is also required to report data to the ALZ-NET registry as a condition of its conditional approval status.
The Hidden Safety Monitoring Burden: ARIA and Mandatory Imaging
Post-approval studies don’t just track cognitive outcomes—they also drive evolving safety requirements that shape how patients must be monitored during treatment. The primary safety concern with anti-amyloid monoclonal antibodies is ARIA (amyloid-related imaging abnormalities), which comes in two forms: ARIA-E (vasogenic edema visible on FLAIR MRI) and ARIA-H (microhemorrhages or hemosiderosis). These are not merely theoretical—they represent actual changes in the brain that patients cannot feel, which is why imaging has become mandatory at specific intervals rather than optional. Current guidance now recommends MRI monitoring before the 3rd, 5th, 7th, and 14th lecanemab infusions, which means a patient on standard maintenance dosing could undergo 4 to 8 additional MRI scans over the course of treatment. This creates both a logistical burden and a financial one, particularly for patients without reliable access to imaging centers or with insurance coverage limitations.
ARIA occurs more commonly in patients carrying the ApoE4 genetic variant, but most patients won’t know their ApoE4 status until tested—introducing uncertainty into counseling about individual risk. Post-marketing pharmacovigilance data reveal the weight of this monitoring. As of recent analysis, the FDA’s Adverse Event Reporting System (FAERS) recorded 1,986 lecanemab-related adverse events affecting 868 patients, with 203 of those patients experiencing serious adverse events including 22 deaths. The most frequently reported events were headache (193 cases), chills (100), fatigue (93), and amyloid-related imaging abnormality—edema or effusion (91 cases). These numbers don’t yet indicate a signal of unexpected harm, but they show that post-approval surveillance continues to identify and catalog real-world adverse effects that emerge beyond the controlled clinical trial setting.
What Real-World Data Tells Us That Clinical Trials May Not Reveal
The transition from controlled trials to post-approval real-world monitoring is where drugs often reveal characteristics missed in the pristine environment of a clinical trial. Trial populations are typically healthier, more adherent, and more carefully selected than the general patient population seeking treatment. Real-world FAERS data begin to sketch a different picture: patients with concurrent medications, variable kidney and liver function, and less ideal circumstances for tolerating infusion-related reactions and imaging-induced anxiety.
The FAERS dataset captures not just serious events but also the texture of what living with the drug feels like: fatigue, chills, and headache reported by dozens of patients suggest that the tolerability profile extends beyond what a single Phase 3 trial might emphasize. Post-marketing surveillance is designed to catch rare or delayed adverse events that a trial of a few thousand patients over 18 months simply cannot detect—a signal that might only become visible when tens of thousands of patients receive a drug over years. This is precisely why the FDA maintains the authority to withdraw approval or impose additional restrictions if post-approval data reveal a safety profile inconsistent with the clinical benefit observed in trials.
The Practical Cost and Access Implications of Post-Approval Monitoring
For patients and caregivers, the post-approval requirements translate into tangible expenses and logistical complexity. Leqembi’s IQLIK subcutaneous autoinjector, approved for maintenance dosing, carries a list price of $375 per autoinjector, equating to $19,500 annually for patients on the standard maintenance schedule. But the drug itself is only part of the cost equation. Average out-of-pocket costs for lecanemab and the required testing—baseline and repeated MRI scans, genetic testing for ApoE4 status, lab work to assess kidney function before dosing—can reach nearly $11,000 annually, even with insurance.
These costs create a stratification in access that post-approval studies are not designed to address. A patient with excellent insurance and nearby access to an imaging center faces a different practical reality than a rural patient or one with limited coverage. The post-approval monitoring requirements, while medically sound for safety, have inadvertently become a barrier to equitable access. Insurance coverage for the drug and associated testing remains inconsistent, and Medicare coverage policies have evolved over time, reflecting ongoing debates about whether the 27% slowing of decline justifies the cost and burden to the health system.
The Limits of Current Trials: Prevention Remains Unproven
While post-approval studies for symptomatic patients continue, the next frontier—using anti-amyloid therapies to prevent symptom onset in cognitively normal individuals—remains largely experimental. TRAILBLAZER-ALZ 3 is currently enrolling approximately 3,300 cognitively normal individuals who have evidence of brain amyloid detected on PET imaging to evaluate whether donanemab can delay symptom development at the preclinical stage. This trial represents the next post-approval frontier, but it also highlights an important limitation: we don’t yet know whether preventing amyloid accumulation in asymptomatic people translates to meaningful benefits, or whether the safety profile of years-long treatment in cognitively normal individuals will be comparable to that in symptomatic disease.
The prevention trials underscore that post-approval studies are iterative. The success of symptomatic trials opened the door to prevention trials, but each new indication and patient population requires its own confirmatory evidence. A cognitively normal person’s tolerance for ARIA or infusion-related reactions may differ from that of someone already experiencing cognitive decline, and the threshold for what constitutes meaningful benefit in a preclinical population may differ as well. Until these prevention trials complete and post-approval monitoring data accumulate, recommending anti-amyloid therapy to asymptomatic individuals remains experimental, even if the drugs are already approved for other populations.
What Happened to Aducanumab and Other Failed Programs
The post-approval pathway is not always a path to success, and aducanumab stands as a cautionary example. Aducanumab received FDA approval under the Accelerated Approval pathway in 2020 based on biomarker data showing it reduced amyloid in the brain, but the sponsor—Biogen—never successfully demonstrated that the drug slowed cognitive decline. The company terminated the ENVISION post-marketing Phase 4 confirmatory study in 2021 and subsequently abandoned the program, effectively admitting that the drug did not meet the clinical benefit standard it had been conditionally approved to meet. This outcome, while frustrating for patients who had hoped for a treatment, also illustrates that the FDA’s post-approval oversight mechanism worked: a drug that could not verify its benefit did not remain on the market indefinitely.
The aducanumab experience shaped how the FDA and sponsors approached subsequent anti-amyloid candidates. Lecanemab’s successful confirmatory trial, by contrast, was completed with positive results, giving the company and regulators confidence in the drug’s place in the treatment arsenal. Donanemab’s approval came with the explicit requirement to report ongoing data to the ALZ-NET registry, a registry-based approach that reflects lessons learned from earlier uncertainties. These different outcomes underscore that post-approval studies are not rubber stamps—they are genuine assessments with real consequences.
2026 Milestones and What the FDA Is Monitoring This Year
The regulatory calendar for Alzheimer’s drugs is active in 2026, with several milestones that will inform future post-approval strategies. The FDA has a May 24, 2026 target action date for approval of Leqembi’s at-home weekly subcutaneous starting dose formulation, which represents a shift in how the drug might be administered—potentially reducing the burden of clinic visits and infusion center logistics. Eight Phase 3 clinical trials related to anti-amyloid or downstream Alzheimer’s therapies are expected to reach their primary completion dates in 2026, while 29 Phase 2 trials will conclude, creating a substantial influx of post-approval and pipeline data that will inform regulatory decisions and clinical practice for the remainder of the decade.
These 2026 trials and approvals matter because they will shape the evidence base on which post-approval monitoring strategies are built. A successfully approved at-home formulation, for instance, would alter the monitoring landscape—home infusions introduce different safety considerations than clinic-based infusions, and the FDA will likely impose specific safety requirements for at-home administration, potentially including mandatory telemedicine oversight or caregiver training. As more data accumulate from ongoing trials and real-world experience with lecanemab and donanemab, post-approval studies will continue to refine what we know about long-term efficacy, safety in diverse populations, and the true cost-benefit profile of these drugs in clinical practice.
- —
